Currently, tumor-infiltrating lymphocytes (TILs)—including subsets of helper CD4+ cells, B cells, NK cells, γδT cells, and myeloid cells—are considered crucial biomarkers in tumor immunotherapy (9). Here, CD4 is linked to neoplasm.